Over the past 3 decades, Doxinate has come to be recognised by the medical community as the
medication of choice for NVP. Within 25 years of its launch, it had been prescribed to over 33 million women.
Doxinate’s vitamin B6 and antihistamine combination has been widely studied for use during pregnancy. It has been included in 25 epidemiological studies involving more than 200,000 women as well as 2 meta-analyses, all of which have confirmed its safety for pregnant women.
Doxinate was the only product to score an ‘A’ - the highest safety rating - in Briggs’ Reference Guide to fetal and neonatal risk.
Doxinate’s delayed-release formula and dosage schedule provides 24-hour
control over NVP symptoms. This prevents the condition from progressing to hyperemesis gravidarum. When administered at an early stage, Doxinate effectively alleviates NVP symptoms and improves the patient’s quality of life.